资源描述：
《尿毒清颗粒联合厄贝沙坦治疗ⅳ期糖尿病肾病的疗效观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。
1、尿毒清颗粒联合厄贝沙坦治疗IV期糖尿病肾病的疗效观察龚丽娜(广东省佛山市南海区第二人民医院肾内科广东佛山528251)【摘要】目的探讨尿毒清颗粒联合厄贝沙坦对IV期糖尿病肾病(diabeticnephropathy,DN)患者的疗效。方法将62例DNIV期患者随机分为厄W沙坦组(对照组，31例)和尿毒清联合厄贝沙坦组(治疗组，31例)。两组初始均服用厄贝沙坦150mg/d,从第三周起可耐受则加量至300mg/d,不耐受者不变、减量甚至退组。治疗组从幵始联用尿毒清颗粒。疗程均为3个月。比较治疗前后两组治疗效果及不良反应，统
2、计每组厄贝沙坦的平均日用量及退组患者情况。结果2组治疗后UAE、Scr、TC、TG、hs-CRP、FIB各指标均较治疗前有改善，治疗组优于对照组(P<0.05)o对照组血钾升高较明显。治疗组1例退组，对照组4例退组。治疗组厄贝沙坦平均用量为174mg/d,对照组为155mg/d。结论较单用厄贝沙坦，尿毒清颗粒联合厄贝沙坦治疗DN1V期患者能更有效减少蛋白尿，保护肾功能，更安全。【关键词】尿毒清颗粒厄贝沙坦糖尿病肾病疗效观察【中图分类号】R453【文献标识码】A【文章编号】2095-1752(2013)13-0115
3、-02ClinicalefficacyofCompoundNiaoduqingparticlesandirbesartaninpatientswithstageIVdiabeticnephropathyGongLina(DepartmentofNephrology,TheSecondPeople’sHospitalofNanhaiDistrict,FoshanCity,GuangdongProvince,Foshan528251,China)【Abstract】ObjectiveToexploretheeff
4、ectofcombinationofNiaoduqingparticlesandirbesartaninpatientswithstageIVdiabeticnephropathy(DN).Methods62patientswithDNIVwererandomlydividedintotheIrbesatangroup(controlgroup,31cases)andNiaoduqingIrbesatangroup(treatmentgroup,31cases).Theinitialallgroupstakingirbe
5、sartan150mg/d,canbetoleratedfromthethirdweekonwardthedoseto300mg/d.Theintoleranceunchanged,reduceorevenwithdrawalgroup.ThetreatmentgroupstartedassociatedwithNiaoduqingparticles.Thecoursewas3months.Comparetwogroupsbeforeandaftertreatmenttherapeuticeffectsandadvers
6、ereactions,theaveragedailyamountofeachgroupofirbesartanandwithdrawalpatients’condition.ResultsAftertreatment,UAE、Scr、TC、TG、hs-CRP、FIBimprovedinbothgroups,thetreatmentgroupwassupertocontrolgroup(P<0.05)。Controlgroupelevatedserumpotassiummoreobvious.Therew
7、as1patientretreatgroupinthetreatmentgroup,and4patientsinthecontrolgroup.Theaveragedoseofirbesartanwas174mg/dinthetreatmentgroup,and155mg/dinanother.ConclusionThecombinationofNiaoduqingparticlesandirbesartanwasmoreeffectivethanirbesartanalonetoreduceproteinuriaand
8、protectrenalfunctioninthetreatmentofDNIV,goodsafety.【Keywords】NiaoduqingparticlesIrbesartandiabeticnephropathyefficacy当今世界，糖尿病患病率急剧上升，DN是糖尿病最主要的微血管病变之一，是导致终末期肾
